Home › Funds › Capricorn Fund Managers Ltd › MLTX
Capricorn Fund Managers Ltd position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Capricorn Fund Managers Ltd reported holding 374,866 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$7.3M, representing 0.58% of its reported portfolio and ranking #49 among its reported holdings. Capricorn Fund Managers Ltd first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Capricorn Fund Managers Ltd's MLTX position evolved
Capricorn Fund Managers Ltd first disclosed a stake in MLTX in Q2 2026 at 374,866 shares (US$7.3M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 374.87K | $7.29M | New |
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 30 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Capricorn Fund Managers Ltd
FAQ
How long has Capricorn Fund Managers Ltd held MLTX?
Capricorn Fund Managers Ltd has disclosed MLTX holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Capricorn Fund Managers Ltd's current position in MLTX?
As of Q2 2026, Capricorn Fund Managers Ltd holds 374.87K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $7.29M, representing 0.58% of its reported portfolio and ranking #49.
Has Capricorn Fund Managers Ltd been buying or selling MLTX?
In the latest 13F filing (Q2 2026), Capricorn Fund Managers Ltd newly opened its position in MLTX.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.